Recent results of ProtecT trial published after 15 years of follow-up demonstrate the absence of difference in prostate cancer-specific survival between active monitoring, radiotherapy, or prostatectomy for PSA-detected, localized prostate cancer patients. These results definitively confirm the essential role of active surveillance as the gold standard for men with low-risk and highly selected intermediate-risk prostate cancer. It underlines the importance of shared-decision making process with patients.
Urologia. 2024 Mar 13 [Epub ahead of print]
Mario Terlizzi, Alberto Bossi
Radiation Oncology Department, Institut Gustave Roussy, Villejuif, France.